Dual-drug approach burns out leukemia cells by pressing accelerator and brake simultaneously
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Pushing the accelerator and the brake at the same time is rarely a good idea. But researchers at the University of Gothenburg are using this approach to treat leukemia. A new drug forces cancer cells to keep working hard even though they have run out of energy. The first study in mice shows very promising results.
A team led by Leif Eriksson at the University of Gothenburg and Boaz Tirosh at Case Western Reserve University in Cleveland has developed a new treatment for acute myeloid leukemia (AML). AML is an aggressive form of cancer affecting the blood and bone marrow, which prevents the production of red and white blood cells. The disease, which affected about 1 million people globally in 2015, requires immediate treatment and primarily affects adults.
Different areas of expertise
"Boaz Tirosh is a biochemist and understands the processes taking place within a cell. It was he who put forward the hypothesis for this treatment. I am a computational chemist and have designed a molecule that enters the cancer cell and alters it in the way we want," says Eriksson, professor of physical chemistry at the University of Gothenburg.
The molecule, named AcTor, inhibits a signaling protein that affects the function of the mTOR protein. mTOR acts as a control center that determines when the cell should grow, build itself up or rest. The researchers' intervention ensures that mTOR continues to promote full cell activity, even though energy production in the mitochondria is shut down using a standard antiproliferative drug.
The combination of treatments means that the cancer cells continue to put their foot down on the accelerator, even while the brake is on. This causes the cells to run amok and die from stress.
"It's a completely new method and does not affect healthy blood cells; furthermore, our studies in mice show that drug resistance is avoided, which can otherwise happen," says Eriksson.
Leukemic stem cells disappeared
The study, published in Molecular Cancer, reports that AcTor had a very strong effect on leukemia in both AML cell lines and primary patient samples, as well as in animal trials, when used in combination with the inhibitor Ixazomib (IXZ). The treatment remained equally effective in TP53-mutant AML, a highly aggressive form of cancer with a poor prognosis and limited treatment options.
Not only were diseased blood cells eliminated using the new method, but leukemic stem cells—which can lead to relapse—also disappeared.
"We also observed that our treatment triggered the release of a protein (ADM2), which could therefore serve as a biomarker for the treatment's response. This could guide future translational and clinical studies," says Eriksson.
Validation in preclinical studies
Work is now continuing to validate the treatment in preclinical and, eventually, clinical studies. There is still a long way to go before this method is ready to treat patients with relapsed or refractory acute myeloid leukemia, who currently face limited options and a poor prognosis.
"Our study is an example of the shift toward focusing research on cancer metabolism within cells, rather than relying solely on methods that damage DNA. Drug development is very expensive, but we hope that our findings will generate sufficient interest to enable us to continue our research into a cure for this serious disease," says Eriksson.
Publication details
Shakti P Pattanayak et al, AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia, Molecular Cancer (2026). DOI: 10.1186/s12943-026-02689-4
Journal information: Molecular Cancer
Key medical concepts
Clinical categories
Oncology Provided by University of Gothenburg Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Dual-drug approach burns out leukemia cells by pressing accelerator and brake simultaneously (2026, September 8) retrieved 8 September 2026 from https://medicalxpress.com/news/2026-09-dual-drug-approach-leukemia-cells.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.